MarketMoodz
HSBC downgrade signals downside risk for Lilly amid obesity-drug scrutiny
HSBC cut Eli Lilly (LLY) to Reduce from Hold and slashed its price target to $850 from $1,070, led by analyst Rajesh Kumar. The note also trims Novo Nordisk (NVO) targets and argues that pricing pressure and competition in obesity drugs could cap Lilly’s upside even as its GLP-1 drugs drive near-term growth.
Key Takeaways
- HSBC lowers Lilly to Reduce with an $850 target, citing upside risk from pricing pressure and competition in obesity drugs.
- Novo Nordisk's target is cut to DKK 280 as 2026 guidance reflects a cautious view on Wegovy/Ozempic dynamics.
- Orforglipron is expected to launch in Q2, offering near-term catalysts but with execution and pricing uncertainty.
- HSBC argues TAM for obesity drugs could be $80-120B by 2032, well below some consensus.
- Markets show mixed signals: Lilly up ~20% over 12 months vs Novo down ~55%; Lilly pre-market move around -0.9% after the downgrade
People Involved
- Rajesh Kumar HSBC Analyst
Entities Involved
- Eli Lilly (LLY) American pharmaceutical company developing GLP-1 therapies
- Novo Nordisk (NVO) Danish pharmaceutical company leading GLP-1 obesity drugs
MarketMoodz Analysis
For investors, the downgrade raises the risk that Lilly's valuation could re-rate lower if obesity-market growth cools. The note emphasizes pricing pressure and intensified competition, implying that upside from Zepbound and Mounjaro may not translate into commensurate earnings if payer dynamics tighten and cash-pay channels shift. The call to rotate toward defensives and stock-picking around Orforglipron's launch adds a tactical dimension to portfolio positioning.
Historically, the obesity-drug wave has proven volatile as governments and payers calibrate coverage and price. Novo Nordisk remains exposed to similar dynamics, even as it navigates slower 2026 growth. The downgrade reflects a broader risk-off tone in healthcare when growth is priced in. Key catalysts to watch include Orforglipron's market performance, payer policy developments, and any updates to Lilly's and Novo's 2026 guidance.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial